Maryland Senate Bill 516 (SB 516) – which took effect on July 1, 2023 – permits adults in the Old Line State who are 21 years old or older to legally possess, home-cultivate, and purchase personal-use quantities of marijuana of up to 1.5 ounces of cannabis flower and/or 12 grams of cannabis concentrates, and up to two mature plants in a private residence.
Maryland voters approved a Marijuana Legalization Amendment in November 2022 to establish regulations governing the production and sale of cannabis to adults in the state. The approved regulations triggered the enactment of House Bill 837 (HB 837) which established new adult-use possession limits. Maryland Governor Wes Moore approved SB 516 in May 2023.
The percentage of employees in the United States workforce who tested positive for marijuana following an on-the-job accident increased to its highest level in 25 years in 2022, according to the analysis of Drug Testing Index™ (DTI) from Quest Diagnostics, the world’s leading provider of diagnostic information services, a news release from Quest Diagnostics stated.
The analysis from Quest Diagnostics found that post-accident marijuana positivity of urine drug tests in the general U.S. workforce was 7.3 percent in 2022, an increase of 9 percent compared to 6.7 percent in 2021. In addition, post-accident marijuana drug test positivity has increased by 204.2 percent in the 10-year time frame from 2012 to 2022.
“These increases in post-accident marijuana positivity correspond with legalization of marijuana in certain states,” according to the news release, which added that 21 states and the District of Columbia (D.C.) have legalized the recreational use of marijuana while 38 states and D.C. have legalized medical use, although either kind of use remains illegal under federal law.
ClearStar is a leading global Human Resources technology company specializing in background checks, drug testing, and occupational health screening. ClearStar offers employers performing drug testing more than 15,000 convenient drug test locations and 3,600 rated clinics. To learn more about workforce screening solutions from ClearStar, contact us today.
© 2023 ClearStar. All rights reserved. – Making copies of or using any part of the ClearStar website for any purpose is prohibited unless written authorization is first obtained from ClearStar. ClearStar does not provide or offer legal services or legal advice of any kind or nature. Any information on this website is for educational purposes only.
Let's start a conversation
Thomas Ahearn - Digital Content Editor
Thomas Ahearn is a Digital Content Editor at ClearStar, a leading Human Resources (HR) technology company specializing in background checks, drug testing, and occupational health screening. He writes about a variety of topics in the background screening industry including Artificial Intelligence (AI), "Ban the Box," class action lawsuits, credit reports, criminal records, drug testing, Equal Employment Opportunity Commission (EEOC), Fair Credit Reporting Act (FCRA), Form I-9, identity theft, privacy, social media screening, and workplace violence.
At ClearStar, we are committed to your success. An important part of your employment screening program involves compliance with various laws and regulations, which is why we are providing information regarding screening requirements in certain countries, region, etc. While we are happy to provide you with this information, it is your responsibility to comply with applicable laws and to understand how such information pertains to your employment screening program. The foregoing information is not offered as legal advice but is instead offered for informational purposes. ClearStar is not a law firm and does not offer legal advice and this communication does not form an attorney client relationship. The foregoing information is therefore not intended as a substitute for the legal advice of a lawyer knowledgeable of the user’s individual circumstances or to provide legal advice. ClearStar makes no assurances regarding the accuracy, completeness, or utility of the information contained in this publication. Legislative, regulatory and case law developments regularly impact on general research and this area is evolving rapidly. ClearStar expressly disclaim any warranties or responsibility or damages associated with or arising out of the information provided herein.
